Latest

3 stories

Hide weekly roundups

Tuesday, September 22

FDA tells Compass Therapeutics to run survival trial before BLA for tovecimig

Compass disclosed on September 22, 2026 that the FDA wants a trial showing survival benefit before it accepts a BLA filing for tovecimig in biliary tract cancer, but the company disputes that a new study is needed.

SEC filing

Thursday, August 6

Quarterly updateCompass Therapeutics

Compass Therapeutics awaits FDA input on tovecimig biliary cancer data

The company said it expects to hear from the FDA in the third quarter of 2026 on Phase 2/3 results for tovecimig ahead of a possible BLA filing later this year.

SEC filing

Tuesday, July 28

Compass Therapeutics posts Phase 2 results for CTX-009 in metastatic colorectal cancer trial

Trial updateCompass Therapeutics CTX-009